Pfizer Inc. $PFE Stock Position Reduced by First Pacific Financial

First Pacific Financial decreased its stake in Pfizer Inc. (NYSE:PFE) by 32.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 85,317 shares of the biopharmaceutical company’s stock after selling 40,518 shares during the quarter. First Pacific Financial’s holdings in Pfizer were worth $2,124,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank increased its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the last quarter. Twin Peaks Wealth Advisors LLC bought a new position in Pfizer during the second quarter valued at approximately $134,000. Finally, JT Stratford LLC raised its position in Pfizer by 72.4% during the second quarter. JT Stratford LLC now owns 17,521 shares of the biopharmaceutical company’s stock valued at $425,000 after acquiring an additional 7,359 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. HSBC upped their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.19.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court orders Poland and Romania to accept €1.9B ($2.2B) of Pfizer COVID-19 vaccine deliveries — a material recognized/near‑term revenue win that supports sales visibility. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: England offered Pfizer’s RSV vaccine to an additional ~3 million older adults — a rollout expansion that could lift recurring vaccine revenue in key markets. Pfizer RSV vaccine offered to 3M more older adults in England
• Positive Sentiment: Technicals and sentiment remain constructive in parts of the market — commentary notes PFE trading above its 50- and 200-day SMAs and outpacing peers at times, which can support short‑term buying interest. PFE Stock Trades Above 200 & 50-Day SMA for 3 Months
• Neutral Sentiment: Pfizer is closing its South San Francisco research site to cut costs and concentrate R&D investments — could boost near‑term margins but raises questions about long‑term pipeline capacity. Pfizer Site Closure Puts Cost Focus And R&D Productivity In Spotlight
• Neutral Sentiment: Corporate reshaping: Pfizer exits part of the ViiV HIV venture as partners adjust ownership — reduces direct HIV exposure but simplifies portfolio. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Investor pieces on valuation and options (covered-call strategies) highlight yield attraction but offer no company‑level catalyst — useful for income investors but neutral for PFE’s share direction. Boost Pfizer’s Already Hefty 6% Dividend Yield With A Covered Call
• Negative Sentiment: U.S. policy risk: the Trump administration proposed tariffs up to 100% on branded drugs — unless makers agree to U.S. pricing deals or on‑shore manufacturing commitments — creating large downside regulatory risk for branded drug revenue and margins. Trump Administration Unveils Up to 100% Tariff on Branded Drugs
• Negative Sentiment: Clinical/program execution concerns: Pfizer and BioNTech paused recruitment for a U.S. trial of an updated COVID vaccine due to low enrollment — signals demand softness for new COVID boosters and complicates future vaccine growth. Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Analyst/watchdog skepticism: commentary argues Pfizer’s large dividend may mask slower organic growth, keeping some investors cautious about forward earnings momentum. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem

Pfizer Price Performance

NYSE PFE opened at $28.37 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.75. The company has a fifty day simple moving average of $27.03 and a 200 day simple moving average of $25.79. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market cap of $161.29 billion, a P/E ratio of 20.86 and a beta of 0.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm posted $0.63 EPS. The business’s quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.